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Aim: To identify patterns and characteristics of polypharmacy among elderly residents in Danish nursing
homes in the Northern region of Denmark. Materials & methods: Twenty-five nursing homes were con-
tacted, where each supplied 20 randomly selected anonymized residents’ information. Residents were
65 years or older, concurrently taking five or more medications. Drug–drug interactions and potential
adverse effects were investigated. Results: One hundred residents (68% females; 32% males) were in-
cluded. The most prevalent co-morbid condition was cardiovascular disease, and the most prevalent medi-
cations were for gastrointestinal- and metabolism-related conditions. Age influenced the number of drugs
(p = 0.013) and drug–drug interactions per resident (p = 0.039), with a positive correlation. Conclusion:
Elderly residents of the studied nursing homes were potentially affected by an inappropriate polyphar-
macy.
Lay abstract: Multimorbidity is common among elderly and a leading factor for polypharmacy. We con-
ducted this study on 100 Danish elderly residents (>65 years, on ≥5 medications) in 25 nursing homes,
anonymously and randomly chosen in Northern region of Denmark, to find characteristics of potential
inappropriate polypharmacy. We found that age influenced the number of drugs (p = 0.013) and number
of drug–drug interactions per resident (p = 0.039), but no sex-related difference was evident. Positive cor-
relations were present between the number of drugs and drug–drug interactions. Elderly residents of the
studied nursing homes were potentially affected by an inappropriate polypharmacy.
First draft submitted: 13 March 2020; Accepted for publication: 1 May 2020; Published online:
29 May 2020
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The percentage of the population above the age of 60 years old has increased drastically throughout the last few
decades. It is estimated that a twofold increase of the world’s elderly population will occur by 2050, reaching
nearly 2.1 billion people aged 60 or above [1]. Age has been demonstrated to have an evident association with
multimorbidity [2], which is the coexistence of multiple long-term health conditions in a person [3]. It is estimated
that up to 95% of the population aged 65 years or older are affected by multimorbidity [3]. In a study performed
in a Swedish nursing home, residents exhibited on average 16.8 ± 5.3 separate chronic health problems [4]. The
top ten multimorbidities have been reported as hypertension, Type 2 diabetes, depression, lipid disorders, chronic
obstructive pulmonary disease, ischemic heart disease, atrial fibrillation, obesity, asthma and dementia [5]. The
most common affected organ systems have been identified as cardiovascular system followed by the central nervous
system (CNS). Accordingly, the three most commonly prescribed drugs have been recorded as psycholeptics, cardiac
medications and diuretics [6].
Multimorbidity results in an increased risk of hospitalization, loss of physical functioning, depression, premature
death and polypharmacy [3,7,8]. No consensus currently exists for definition of polypharmacy. A systematic review
of 110 studies on polypharmacy has stated that the most commonly used definition is based on concomitant
consumption of five or more (>5) drugs [8], which has been reported in 44% of individuals aged 65 years or
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above [9]. Polypharmacy, is associated with higher risk of adverse outcomes such as frailty, disability, mortality and
falls [10]. In one hand, polypharmacy seems necessary to manage multimorbidity in the elderly to target pathogeneses
of a diverse range of diseases [11]. On the other hand, risks may arise when inappropriate polypharmacy exists,
which is defined as an irrational prescription of too many drugs [12]. Appropriate polypharmacy occurs when the
decisions concerning the prescription of multiple drugs to one patient rely on evidence-based practices, achieving
the desired clinical effect without compromising the patient’s quality of life by acquiring a reduction in drug
toxicity [13]. However, inappropriate polypharmacy occurs when the prescription of multiple drugs to one patient
fails to achieve the desired therapeutic effect, only resulting in increased risks and harmful health outcomes [13].
Inappropriate polypharmacy is a worldwide problem [12,14], including Scandinavian countries. For instance,
Nyborg et al. [15] investigated use of potentially inappropriate medications (PIMs) among elderly living in nursing
homes in Norway and demonstrated that 43.8% of the residents were prescribed at least one PIM, while 9.9%
were treated with at least three PIMs. The prevalence of PIMs was also higher among females [15]. Inappropriate
polypharmacy results in an increased risk of avoidable negative health outcomes [13] and has been associated with
higher risks of adverse drug events (ADEs) [16], drug interactions, for example, drug–drug interactions (DDIs) [17],
medication nonadherence and functional decline [18]. A subcategory of ADEs are adverse drug reactions (ADRs),
defined as harmful or unpleasant reactions related to use of drugs [19]. Hanlon et al. [20] determined that polypharmacy
consistently increases the risk of ADRs in elderly patients. In particular, it has been reported that this issue is higher
in nursing homes [13], and patients on nine or more drugs are more than twice as likely to experience an ADR
than those receiving less than nine [21]. This poses a serious problem because ADRs are difficult to distinguish
from symptoms that are already present in the elderly, such as delirium and falls [22], making it difficult to choose
the correct treatment, which can possibly lead to further inappropriate prescriptions [14]. Furthermore, the risk of
hospitalization in the elderly with polypharmacy rises through an increase in ADEs [23]. Managing polypharmacy
in the elderly, therefore, can be very challenging [22] and time consuming [24]. It is because of age-related changes
in the physiology of the elderly population that cause alterations in drug disposition and metabolism [25–27], one
example is the decline in the capacity of Phase I reaction enzymes (CYP450) [28]. Doan et al. [29] determined that
80% of the hospitalized elderly population with polypharmacy have a potential CYP450-mediated DDI, with the
prevalence of potential DDIs increasing with the number of prescriptions.
Collectively, the higher prevalence of multimorbidity and polypharmacy, combined with age-related alterations
in pharmacokinetics and pharmacodynamics, makes the older population more susceptible to ADEs [30]. Polyphar-
macy is also associated with anxiety or excitability, sleep difficulties, discomfort, weakness, confusion, tremors,
hallucinations and feeling dizzy, demonstrating a negative impact on quality of life among elderly population [31].
Besides patient’s safety, inappropriate polypharmacy poses an economic burden to healthcare system [32], due to
hospital admissions or nonadherence to medications [14]. A Japanese cohort study highlighted that polypharma-
ceutical patients on one or more PIMs have a significantly higher hospitalization risk and more outpatient visit
days, resulting in a 33% increase in healthcare cost when compared with polypharmaceutical patients on no
PIMs [33]. Similar results have been found in Scandinavia, where a Swedish-based register study [34] determined
that individuals on multiple medications (>5) account for 78.8% of total prescription medication acquisition
costs. When compared with nonpolypharmaceutical patients, polypharmaceutical patients experienced increased
prices per defined daily dose, with patients on ten or more prescribed drugs paying the most per dose [34]. Another
Swedish study [35] has demonstrated that the increase in polypharmacy in recent years accounts for a large part of
the increase in prescription drug expenditure. By comparing the prescription drug expenditure in 2005 and 2009,
Hovstadius et al. [35] determined that the increase in polypharmacy between 2005 and 2009 could explain the entire
increase in prescription drug expenditure in Sweden for that period. Several lists and guidelines have been developed
around the world in attempt to prevent inappropriate polypharmacy and proper treatment of co-morbidities [36],
including the US Beers criteria [15], Norwegian General Practice criteria [37], and Screening Tool of Older Patients’
Prescriptions (STOPP) [38–40]. A modified version of the STOPP criteria is currently in use in Denmark [39,41],
which has been developed by the Danish Geriatrics Society [42].
While some older studies have investigated patterns of polypharmacy in different regions in Denmark, including
Funen [43] and Jutland [44], to the best of our knowledge, no recent Danish study has examined the pattern of
polypharmacy and relationship between polypharmacy and DDIs, ADEs and ADRs, with a focus on nursing
homes. Therefore, the aim of this study was to identify patterns and characteristics of polypharmacy in the elderly
population living in nursing homes in Aalborg municipality, Northern region of Denmark, by investigating the
DDIs and potential adverse effects. We proposed that our study could provide evidence for the existence of
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polypharmacy and potentially inappropriate polypharmacy in the elderly population above 65 years living in these
nursing homes.
Methods
Study population
This study was conducted in 2019 based on medication lists obtained from nursing homes in Aalborg municipality,
Northern Jutland, Denmark. The target population of this study was the polypharmaceutical elderly. Elderly
was defined as being over 65 years of age, while polypharmacy was defined as the concurrent use of five or
more prescription-based pharmaceutical dosage forms. In this definition, the time-limited medications, such as
antibiotics, were not included, since the five or more medications should be taken regularly for a longer period
of time. Furthermore, vitamins and food supplements that do not need a prescription (e.g., calcium, D vitamin,
multivitamin) were not included in this category; hence, they were excluded from calculation of the total number
of medications taken by each patient. Supplements that require a prescription, which in this study were vitamin
B12 and potassium chloride, were included.
The participants in this study were recruited in the period of 7–27 November 2019, from nursing homes located
in different parts of Aalborg municipality with following postal codes: 9000 Aalborg, 9200 Aalborg south west,
9210 Aalborg south east, 9220 Aalborg east, 9270 Klarup, 9280 Storvorde, 9310 Vodskov, 9382 Tylstrup and
9400 Noerresundby. The different nursing homes were identified using a publicly available list of nursing homes
in Aalborg municipality [45].
Due to the nature of this study, the ethical approval from the North Denmark Region Committee on Health
Research Ethics was not required. Since participants’ information was provided anonymously by nursing homes,
no consent form was required.
Study process
In total, 25 nursing homes were identified and contacted (total resident capacity = 1165) by personal attendance
in order to determine their interest in participating in this study voluntarily. Each nursing home was asked to
supply the following information from 20 randomly selected residents among those aged 65 years or older, who
were concurrently taking five or more medications: age, sex, co-morbidities and medication list. Each nursing staff
was asked to anonymize the data for each resident before turning it over in order to comply with the general data
protection regulation, which is currently in effect in the European Union. Hence, the study remained anonymous.
Recruitment process is depicted in Figure 1.
When illustrating the total resident capacity, it is important to state that this number does not reflect the actual
number of residents at nursing homes. The capacity number has been reported instead of the actual number of
current residents, since the number of residents is continuously changing.
The nursing homes that expressed interest were given a period of 1 week to consider whether or not they wanted
to participate, followed by a period of 1 week to obtain the data. Afterward, the requested information was either
collected from the nursing homes in person or received by E-mail. The nursing homes that refused to participate
expressed that this was due to lack of time or nursing staff, participation in other projects/studies, or other reasons.
Data analysis
After receiving the datasets, data management was performed using Google sheet. The data were collected in
three separate sheets, of which the first contained age, sex and co-morbidities; the second contained the individual
medication lists; and the third contained the identified DDIs among the medications. In the first sheet, the
co-morbidities were divided into following classes: ‘cardiovascular,’ ‘central nervous system,’ ‘dermatological,’
‘endocrinological,’ ‘eyes and ears,’ ‘gastrointestinal,’ ‘musculoskeletal,’ ‘pulmonal,’ ‘psychological’ and ‘urogenital.’
The co-morbidities were indicated as numbers, which means a total number of co-morbidities was defined and
recorded.
Prescription medications taken by each subject of the study were sorted in the second sheet according to their
Anatomical Therapeutic Chemical (ATC) code, which has been the recommended classification system for drug
utilization studies since 1981 by the WHO (Geneva, Switzerland) [46]. This categorization was performed at the
second level of the ATC code, meaning that drugs were sorted according to their therapeutic subgroup (e.g., ‘A01,
stomatological preparations,’ ‘A02, drugs for acid-related disorders’) [46].
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Contacted
25 nursing homes
(total resident capacity = 1165)
Participating
8 nursing homes
(total resident capacity = 345)
Total number of
dataset requested
(n = 160)
Total number of
dataset received
(n = 105)
Total number of
dataset included
(n = 100)
Total number of
excluded dataset 
(n = 5)
Number of dataset
not received
(n = 55)
Not participating
17 nursing homes
(total resident capacity = 820)
Figure 1. Flowchart illustrating the study steps of recruitment of the residents’ information.
The third sheet was completed utilizing two different drug interaction databases. One is run by the Danish
Medication Agency [47] and the other by the US FDA [48]. Both databases were used to identify potential DDIs
among the different medications. In the FDA database, the potential DDIs were divided into minor, moderate and
major severities. The minor DDIs were clinically insignificant and could be used together, if a monitoring plan was
made. The moderate DDIs were of modest clinical significance, these combinations should usually be avoided or only
used under special circumstances. The major DDIs were highly clinically significant, whereby these combinations
should be avoided [48]. In the Danish database, minor potential DDIs were those with clinical consequences
known to be insignificant or nonexistent. Moderate potential DDIs were combinations of drugs that can be used
therapeutically, if certain precautions are taken (e.g., dosage adjustments or changing the timing of ingestion).
Major potential DDIs were combinations that are contraindicated or combinations that consisted of at least one
drug with no scientifically proven effect [47]. In the database run by the FDA, Microlax (sodium lauryl sulfoacetate),
Bromazepam, Flupentixol, Thiamazol, Zuclopenthixol, Moxonidin, Lercanidipine and Chlorprothixen were not
available, due to the lack of approval in the USA. These drugs could not be checked for any potential interactions
using the FDA database. After managing the data in Google sheets, different illustrations of data were made,
including tables, graphs and pie charts.
10.2144/fsoa-2020-0039 Future Sci. OA (2020) FSO590 future science group
Polypharmacy among Danish elderly in nursing homes Preliminary Communication
Table 1. Demographic characteristics divided into four age groups. Values are expressed as number of subjects and
percentages.
Characteristics Age (years) Total
65–74 75–84 85–94 95+
Population 14 (14%) 44 (44%) 36 (36%) 6 (6%) 100
Sex
– Female 6 (8.8%) 32 (47.1%) 24 (35.3%) 6 (8.8%) 68
– Male 8 (25%) 12 (37.5%) 12 (37.5%) 0 (0%) 32
Co-morbidities
– 0–4 4 (12.5%) 12 (37.5%) 12 (37.5%) 4 (12.5%) 32
– 5–9 10 (16.1%) 29 (46.8%) 21 (33.9%) 2 (3.2%) 62
– 10+ 0 (0%) 3 (50%) 3 (50%) 0 (0%) 6
Drugs
– 5–9 11 (16.2%) 23 (33.8%) 29 (42.6%) 5 (7.4%) 68
– 10+ 3 (9.4%) 21 (65.6%) 7 (21.9%) 1 (3.1%) 32
Statistical analysis
The following statistical tests were performed using the software IBM SPSS Statistics version 25 for Mac OS X. A
statistical significance level of 0.05 and a 95% CI were used to state whether a statistical significance was present.
Prior to the statistical tests, all data (age, sex, number of drugs and number of DDIs) were tested for normal
distribution by using the Shapiro–Wilk test.
Three nonparametric tests were performed. A Mann–Whitney U test was utilized to compare the number of
drugs and the number of DDIs among the female and male residents and the Kruskal–Wallis test was performed to
compare the number of drugs and the number of DDIs among four different age groups (65–74; 75–84; 85–94;
95+). The results from both the Mann–Whitney U and the Kruskal–Wallis tests are presented as median (25–75
percentiles). A Kendall’s tau-b correlation was performed to investigate the relationship between the number of
drugs and DDIs, number of drugs, age and the DDIs between the two databases.
Results
Demographics
One hundred (n = 100) subjects from eight different nursing homes were identified as eligible for data analysis. The
mean (± standard deviation) age in this population was 82.9 ± 7.7 years and out of 100 subjects, 68% were females.
This population presented on average 5.8 ± 2.2 co-morbidities, taking on average 8.5 ± 2.6 prescription-based
pharmaceutical dosage forms. The demographics of these subjects are presented in Table 1.
Co-morbidities & medications
A total of 587 co-morbidities among the 100 residents were registered. As shown in Figure 2, the cardiovascular
system was the most affected system with 157 identified co-morbidities. The second most affected system was the
musculoskeletal system (86 co-morbidities), followed by the CNS (79 co-morbidities).
A total of 848 prescriptions were identified and categorized according to the ATC codes. Table 2 displays the
sorting of these prescription drugs into their anatomical main groups.
Drug–drug interactions
Figure 3 illustrates the distribution of minor, moderate and major potential DDIs for both the FDA and Danish
drug interaction databases. When inspecting the data from the Danish database (A), the minor DDIs made up the
majority (68.6%) of the total number of interactions (n = 226). Comparatively, the moderate potential interactions
were accountable for the majority (76.8%) of the total number of potential interactions (n = 786), when inspecting
the data from the FDA database (B).
In Table 3, the ten most common DDIs were identified, of which the most common ones were Furosemide and
Metoprolol (number of cases = 13). Among the ten most common DDIs, only DDIs of moderate severity were
identified, which means no major DDIs were presented. Furthermore, the potential clinical effects of these DDIs
are presented. The minor DDIs were not included.
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Figure 2. The distribution of co-morbidities by affected systems.
CNS: Central nervous system; GI: Gastrointestinal.
Table 2. The distribution of prescribed medications by the Anatomical Therapeutic Chemical codes.
Overall drug classes Number of prescriptions identified Number of patients receiving drugs Average no. of drugs received by each
subject with 1≤ active prescription
Alimentary tract and metabolism (A) 240 92 2.6
Blood and blood-forming organs (B) 64 62 1.0
Cardiovascular system (C) 191 83 2.3
Dermatologicals (D) 14 12 1.2
Genitourinary system (G) 16 14 1.1
Systemic hormonal preparations (H) 15 15 1
Anti-infectives for systemic use (J) 8 8 1
Antineoplastic and immunomodulating
agents (L)
5 5 1
Muscular–skeletal system (M) 27 27 1
CNS drugs (N) 219 83 2.6
Antiparasitic products (P) 2 2 1
Respiratory system (R) 18 15 1.2
Sensory organs (S) 24 13 1.8
Other drugs† 5 5 1
†Other drugs include categories of drugs, which only contained one prescription. These are: digestives including enzymes (A09), antianemic preparations (B03), antibiotics and chemother-
apeutics for dermatological use (D06), antivirals (J05), anti-inflammatory and antirheumatic preparations (M01).
CNS: Central nervous system.
Comparisons
The Shapiro–Wilk test of normality revealed no significance for co-morbidities, sex or DDIs in both the FDA and
the Danish databases, whereas a significance was observed for age (p = 0.330). This means that data from sex,
co-morbidities, number of drugs and DDIs did not follow a normal distribution, whereas the data from age were
normally distributed.
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Figure 3. The distribution of potential drug–drug interactions found in the Danish drug interaction database (DK)
and the FDA drug interaction database (USA). The DDIs were divided into three categories based on severity: minor,
moderate and major.
DDI: Drug–drug interaction.
Table 3. The ten most common moderate and major drug–drug interactions identified in the Danish and the FDA drug
interaction databases. The potential clinical effects and the severity based on clinical significance are from the databases.
The minor drug–drug interactions were not included.
Rank DDI Number of cases Potential clinical effect Severity
1 Furosemide + Metoprolol 13 Hyperglycemia and
hypertriglyceridemia
Moderate
2 Furosemide + Pantoprazole 11 Hypomagnesemia Moderate
3 Furosemide + Sodium
picosulfate
9 Fluid and electrolyte
disturbances
Moderate
4 Metoprolol + Amlodipine 9 Further reductions in heart
rate, cardiac conduction and
cardiac contractility
Moderate
5 Clopidogrel + Pantoprazole 8 Reduced bioactivation of
clopidogrel and the
therapeutic efficacy
Moderate
6 Metformin + Insulin 7 Hypoglycemia Moderate
7 Mirtazapine + Metoprolol 7 Hypotension Moderate
8 Furosemide + Insulin 7 Hyperglycemia, glucose
intolerance, new-onset
diabetes mellitus and/or
exacerbation of pre-existing
diabetes
Moderate
9 Furosemide + Metformin 7 Increased metformin levels
potentially leading to lactic
acidosis
Moderate
10 Atorvastatin + Clopidogrel 6 Reduced bioactivation of
clopidogrel and its antiplatelet
effect
Moderate
Age
The results from the Kruskal–Wallis test comparing the association between number of drugs per resident and the
different age groups are presented in Table 4. The results showed significant differences (p = 0.013) between the
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Table 4. The median (25–75 percentiles) number of drugs and drug–drug interactions in the Danish and the FDA
databases in the four different age groups.
Age (years) Number of drugs DDI (Danish database) DDI (FDA database)
65–74 8 (6.5–9.5) 1 (0–4) 6 (4–9.5)
75–84 9 (8–11) 2 (1–4) 7.5 (4–13.75)
85–94 7 (6–9) 1.5 (0.25–3) 5 (2.25–7)
95+ 7 (6–9) 1 (1–1) 4 (1–7)
DDI: Drug–drug interaction.
Table 5. The median (25–75 percentiles) number of drugs and drug–drug interactions in the Danish and the FDA
database for females and males.
Sex Number of drugs DDI (Danish database) DDI (FDA database)
Female 9 (7–10) 2 (1–3) 6 (3–12)
Male 7.5 (6–9.75) 1 (0.25–3) 6 (2.25–8)
DDI: Drug–drug interaction.
four different age groups. Furthermore, an investigation on the relation between the number of DDIs per resident
and age groups was performed by using the Kruskal–Wallis test. As seen in Table 4, the highest number of DDIs per
resident was observed in the age group of 75–84 years old. A statistical significance in the FDA database (p = 0.039)
was revealed, however no significant difference was observed in the Danish database (p = 0.122).
Sex
As seen in Table 5, there was a higher number of drugs per resident among the females compared with the males,
however, this was not significant (p = 0.070). Furthermore, a Mann–Whitney U test was performed to analyze if an
association exists between the number of DDIs per resident and sex, the results of which are illustrated in Table 5.
No significant difference was found in the number of DDIs per resident between females and males in the FDA
(p = 0.269) or the Danish database (p = 0.397).
Correlations
Kendall’s tau-b performed on the number of drugs per resident and age, revealed a correlation coefficient of -0.151,
which indicates a minor inverse correlation between these two variables, suggesting that as age increases the number
of drugs decreases. Kendall’s tau-b was also performed on data including number of drugs and the number of DDIs
per resident (both in the FDA and Danish database). The correlation coefficients were 0.400 between DDIs in
the Danish database and the number of drugs, and 0.548 between DDIs in the FDA database and the number of
drugs. These correlation coefficients indicate the presence of positive correlations between all variables, meaning
that as one variable increases, the other also increases.
Discussion
This preliminary study provides the first evidence of potentially inappropriate polypharmacy existing in Danish
elderly resident homes, located at Aalborg municipality. Findings from this study, therefore, must be viewed as a
starting point of research concerning polypharmacy in Danish elderly resident homes.
Demographics
In the present study, 100 residents from nursing homes in Aalborg municipality were included, of which 68%
were females. Females constitute 54% of the Danish elderly population [49]. The observed difference between the
general elderly population and the sample population in this study could suggest that females are more susceptible
to polypharmacy and thus inclusion in the study, which would be in accordance with previous findings [33,50,51].
However, one study of European nursing home residents found that 73% of a total study population of 4023
subjects were females [51]. This indicates that the high percentage of females is a reflection of the over-representation
of females among nursing home residents in Europe. This might be attributed to sex-based differences in mortality,
a difference that increases with age [52].
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Furthermore, the mean age of the present population was 82.9 ± 7.7 years. This number is comparable to
numbers found across Europe. One study determined an average age of 83.5 ± 9.4 years among nursing home
residents across seven different European countries [51]. Akner’s subjects also were 85 ± 7 years of age in a nursing
home in Sweden, pointing out to similar results in Scandinavia [4].
Collectively, the demographics of the subjects included in this study seem representative of Danish nursing home
residents in general. This is supported by a national study conducted by the Danish Ministry of Health (Sundheds-
og Ældreministeriet) [53]. They demonstrated that on average, 68% of nursing home residents in Denmark were
females. While a mean age for current residents of nursing homes was not reported, they did find that the average
age for new residents in nursing homes was 83.7 years of age, with residents on average living in nursing homes for
2 years and 8 months, pointing out to a true mean slightly higher than 83.7 years.
Co-morbidities & medications
Among the residents, an average of 5.8 co-morbidities was identified by asking nursing home staff to provide
information on co-morbidities present in any given subject, which they may have done in a variety of ways. This
number is in contrast to the findings by Akner [4], who found an average of 16.8 ± 5.3 chronic health problems
among 70 residents from a Swedish nursing home. While this difference could be due to a true difference in
frequency of multimorbidity between nursing homes, it most likely reflects methodological differences. Akner [4]
combined medical history, clinical examinations and patient history to assemble a more complete impression of
the health status of the participants, leading to a higher sensitivity in detecting chronic diseases.
The present study identified that the most commonly affected system was the cardiovascular system, followed
by the musculoskeletal system and the CNS. This is not in accordance with previous findings. Akner [4] identified
that the most common co-morbidities were of neuropsychiatric, cardiovascular and gastrointestinal nature. These
differences might be due to an over-representation of neuropsychiatric disorders, which were present in all 70
residents in his study [4].
The number of prescribed medications per resident in this study was 8.5 ± 2.6, of which the three most
commonly prescribed medications targeted the alimentary tract and metabolism, CNS and cardiovascular system.
This is more than the 6.6 ± 3.2 prescribed continuously taken medications that Akner determined among the 70
residents in a Swedish nursing home [4]. This finding most likely stems from the inclusion criteria of more than five
drugs in the present study skewing the average number of medications. However, it has been demonstrated that
this cutoff of more than five drugs has predictable clinical discriminatory properties [10].
Another study [6] demonstrated that the three most commonly prescribed medications were psycholeptics, cardiac
medications and diuretics, which are related to the systems identified as the most common affected systems in the
present study. The classification of drugs according to the ATC codes conducted by Straand et al. [6] confirms this
by identifying the CNS as the most commonly medicated system, followed by the cardiovascular system.
An inverse correlation between age and number of drugs was detected. This finding is counterintuitive, as it is
well known in the literature that advanced age and polypharmacy are associated [9,27]. However, when dividing the
population into four subgroups, the comparison of the of number of drugs demonstrated a statistically significant
difference. The highest number of drugs per resident, based on medians, was among 75–84 year olds, while the
lowest number of drugs per resident was seen among the elderly above the age of 85 years. These findings are in
line with the results from the SHELTER study [51], which demonstrated fewer cases of excessive polypharmacy
(>9 drugs) in the oldest nursing home residents. It has been proposed that this inverse correlation is caused by
the nature of end-of-life care. When starting a new therapeutic regimen, remaining life expectancy is weighed
against time required for therapeutic effect. The risk of ADRs is also higher in this patient group. These factors
in combination can lead to fewer cases of excessive polypharmacy in the oldest population [54]. There is a known
association between multimorbidity and polypharmacy [3], as such it can be expected that patients living with
polypharmacy have a reduced life span. This number could also reflect that patients on fewer drugs have fewer
co-morbidities and consequently may live longer.
There was an obvious variation in the number of subjects and the distribution of females and males within the
different age groups. The results may have been influenced by these differences between the groups. This makes it
difficult to assign the observed association entirely on each age group.
Additionally, a higher number of coprescribed drugs was observed among females when compared with males.
While this result was not statistically significant, the tendency is in accordance with other studies. Among others,
one study by Venturini et al. [55] highlighted that the number of drugs was higher among females, compared with
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males. It has been found that among Finnish and Norwegian elderly, women are slightly more likely to seek primary
healthcare, which might partly explain the difference between the sexes [56]. Females also tend to report significantly
more morbidity than their male counterparts, a difference that may, in part, be accounted for by gynecological
and obstetrical diagnoses [57]. Accordingly, part of the difference between men and women can be attributed to the
use of contraceptive pills and hormones for menopause [58]. While the sample included in this study was above
65 years, this use of contraceptives might mean that women are more accustomed to the use of drugs throughout
their life and into old age [55].
Drug–drug interactions
In the present study, when the Danish interaction database was used, 226 potential DDIs were identified, of which
most were with the nature of minor severity. In contrast, when the FDA database was used, 786 potential DDIs
were identified, of which most were with the nature of moderate severity. This indicates that the FDA database
had a higher sensitivity for detecting DDIs when compared with the Danish database. One explanation for the
difference between number and severity of potential DDIs reported by the different DDI databases may be that these
databases have different physiological foci. Interaktionsdatabasen.dk is based mainly on pharmacokinetic studies,
while the interaction checker on Drugs.com is based on both pharmacodynamic and pharmacokinetic studies. For
this reason, there might be some pharmacodynamic DDIs that are not included by the Interaktionsdatabasen.dk.
Furthermore, Interaktionsdatabasen.dk is based on data from PubMed and Embase, while Drugs.com is based
mainly on data from the American medical information suppliers. Therefore, while the sensitivity was higher when
using Drugs.com, the fact that the data are based on extraction from a more heterogeneous population, raises
questions about the specificity of the results when applied to the very homogenous Danish population in this
study. In fact, it is a known problem that different DDI screening tools offer different sensitivity and specificity.
Furthermore, it has also been reported that DDI databases under-report clinically relevant DDIs and in some cases,
over report insignificant drug interactions [59,60].
Combining data from both databases, the most commonly identified DDIs were Furosemide and Metoprolol,
followed by Furosemide and Pantoprazole. To the best of our knowledge, no comparable, recent studies have
investigated patterns of DDIs in polypharmaceutical nursing home residents. This means that when comparing
the results of the present study, it is important to note that other studies may have dissimilar study populations.
The identified DDIs were not in accordance with the findings from the study by Sönnerstam et al. [61], who found
the most common clinically relevant DDI to be Furosemide and Citalopram, followed by Acetylsalicylic acid and
Citalopram.
The highest number of DDIs per resident was observed in the age group 75–84 years. No significant relation was
found between age groups and DDIs in the Danish interaction database, whereas a significant difference in DDIs
was determined between age groups in the FDA database. This could be due to the majority of the patients in this
age group (75–84 years) taking a higher number of medications, which can increase the risk of DDIs. Goldberg
et al. [62] highlighted that for patients taking two medications, the risk of DDIs was 13%, compared with 38% for
patients taking five medications and 82% for patients taking seven medications or more.
Additionally, the correlation coefficient comparing the number DDIs per resident in the Danish database and the
number of drugs, indicated a positive correlation (0.400), whereas the correlation coefficient from the comparison
of the number of DDIs per resident in the FDA and the number of drugs indicated a stronger positive correlation
(0.548). These correlations are in accordance with the results from the aforementioned study, which demonstrated
an elevated risk of DDIs when increasing the number of drugs [62]. These findings could be further explained by
the fact that the amount of potential pairwise interactions increases exponentially with each coprescribed drug [63].
No significant difference was observed in the total number of DDIs among males and females in the FDA or the
Danish database. These findings are supported by the medians of DDIs in both males and females, which are nearly
identical. When considering the literature, this finding is unexpected. A study by Venturini et al. [55] reported that
females are more likely to take a higher number of medications than men, putting them at higher risk for potential
DDIs. A summary of our findings compared with other studies is presented in Table 6.
Clinical consequences of DDIs
Information regarding documented clinical consequences for the residents included in this study was not available.
Therefore, we reviewed theoretical and clinically observed adverse effects for the ten most commonly identified
potential DDIs in the present study. Table 7 summarizes the findings.
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Table 6. Summary of the present findings in comparison with previous studies in the literature.
Our findings Others findings
68% of elderly at nursing homes with polypharmacy are females 58% of the population above 65 years living at nursing homes in Denmark are
females [49]
Mean (±SD) age = 82.9 ± 7.7 years In Europe [51], the mean age is 83.5 ± 9.4 years
In Sweden [4], the mean age is 85 ± 7 years
New resident average age in Denmark [64]: 83.7 years
5.8 co-morbidities in average Akner [4] found 16.8 ± 5.3 in average
8.5 ± 2.6 number of medications in average Akner [4] found 6.6 ± 3.2 in average
SD: Standard deviation.
Table 7. Summary of drug–drug interaction and clinical consequence.
Drug–drug interaction Clinical consequence
Furosemide + Metoprolol Hyperglycemia/hypertriglyceridemia
Furosemide + Pantoprazole Hypomagnesemia
Furosemide + Sodium picosulfate Fluid and electrolyte disturbances
Metoprolol + Amlodipine Reduction in HR, cardiac conduction and contraction
Clopidogrel + Pantoprazole ↓ Bioactivation of clopidogrel → No antiplatelet eff.
HR: Heart rate.
The mechanism behind DDIs between Furosemide and Metoprolol is not well known; however, studies suggest
that both β-blockers and loop diuretics can alter the lipid profile by elevating levels of triglycerides [65,66]. β-Blockers
may also contribute to the development of hyperglycemia by diminishing the release of insulin from pancreatic
β-cells [65,67]. Based on the findings of this study, interaction between these two was on top of the list of the
identified DDIs; therefore, caution should be taken when prescribing these two drugs. Further studies are required
to elucidate the potential clinical consequences of using Furosemide and Metoprolol.
The second most common DDI identified in this study was between Furosemide and Pantoprazole. Pantoprazole
and other proton-pump inhibitors have shown to cause hypomagnesemia [67]. Urgent clinical consequences of
hypomagnesemia include tremors, convulsions, delirium and even coma [68]. Since hypomagnesemia is also a side
effect of Furosemide [69], the coadministration of these two drugs without taking the necessary precautions to
maintain a normal serum magnesium concentration could be problematic.
Furthermore, a DDI between Furosemide and Sodium picosulfate was identified. Sodium picosulfate should
be administered with caution when combined with medications that can affect renal function (e.g., Furosemide),
since it may result in an increased risk of fluid and electrolyte disturbances, which may lead to seizures, arrhythmias
and prolonged QT interval [70]. Another identified potential DDI was Metoprolol and Amlodipine. The combined
treatment with β-blockers and calcium channel blockers has additive effects on heart rate, cardiac conduction
and cardiac contractility. Cases have been documented on concurrent treatment with these two classes of drugs
leading to congestive heart failure, hypotension, bradycardia or even cardiogenic shock [71,72]. We identified that
potential DDIs were common when Clopidogrel was used with Pantoprazole, and when Clopidogrel was used
with Atorvastatin. The conversion of Clopidogrel into its active metabolite by CYP450 isoenzymes in the liver
is necessary for Clopidogrel to exert its inhibitory effect on platelet aggregation [73]. Pantoprazole, and other
proton-pump inhibitors have been demonstrated to inhibit CYP450 2C9 and 2C19 in vitro [74], while Atorvastatin
inhibits CYP450 34A [73]. Since CYP450 2C19 and 3A4 play a major role in Clopidogrel bioactivation, the
coadministration of these drugs can reduce the activation and subsequent antiplatelet effect of Clopidogrel [73].
One study by Juurlink et al. [75] has shown an increase in the risk of recurrent myocardial infarction when treating
with proton-pump inhibitors and Clopidogrel, simultaneously. However, this was not the case for Pantoprazole;
hence, the clinical significance is yet to be fully established. Nonetheless, Doan et al. [29] observed that 80% of the
hospitalized elderly population with polypharmacy had a potential CYP450-mediated DDI, thus, it is essential to
be mindful when prescribing multiple drugs that interact with CYP450.
In this study, three of the ten most frequent DDIs included an antidiabetic drug. These DDIs included
Metformin and Insulin, Metformin and Furosemide, and Insulin and Furosemide. Both Metformin and Insulin
can lead to hypoglycemia [76], which is the most common side effect of glucose-lowering drugs in general [76].
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Metformin is regarded as a low-risk drug for hypoglycemia, since it exerts its effect through a glucose-dependent
mechanism [76]. However, several studies have observed an evident association between the use of insulin and higher
risk of hypoglycemia [76]. A hypoglycemic episode leads to an activation of the autonomic nervous system resulting
in minor symptoms, from sweating and palpitations, to more severe symptoms such as cognitive dysfunction and
seizures. Depending on the severity and duration of the episode, hypoglycemia can even result in coma or death [76].
Considering these possible detrimental side effects of glucose-lowering drugs, in particular insulin, it is important
to cautiously manage the treatment of a patient whose conditions require both types of drugs.
When using Furosemide in combination with Metformin, Furosemide increases the plasma concentration level
of Metformin by 22% [77]. The clinical implications of this increase are uncertain [77], but it may be possible that
it can result in lactic acidosis, which is a known reaction to Metformin [78]. When the plasma concentration of
Metformin increases, the risk of this reaction could also increase.
The combination of Furosemide and Insulin can exert an inhibitory effect on the secretion of Insulin from the
β-cells of the pancreas, which can generate a problem for patients receiving Insulin as medication as the patient’s
dose takes endogenous insulin production into account. This can result in hyperglycemia, due to the overall
lower amount of insulin circulating in the blood. To account for this interaction, a dose adjustment should be
considered [79].
Since several of the most common DDIs included antidiabetic drugs, it should also be noted that people with
Type 2 diabetes mellitus are often of advanced age [80] and at a higher risk of polypharmacy, which makes them
more exposed to potential DDIs and side effects [81].
A potential DDI between Metoprolol and Mirtazapine was identified. Newer antidepressants are known to have
cardiovascular side effects [82]. As such, coadministration of Mirtazapine with the β-blocker Metoprolol would
presumably lead to additive hypotensive effects, as well as changes in pulse and/or heart rate. However, it has been
observed that coadministration of Metoprolol and Mirtazapine is safe with no clinically significant DDIs [83]. In
fact, this lack of clinical adverse effects has been documented to such a degree that Mirtazapine has been used as
the negative control in a case–control study of interactions between Metoprolol and selective serotonin reuptake
inhibitors [84].
The most common, potentially clinically relevant DDIs identified in this study were of moderate severity;
however, major potential DDIs also occurred. Three of them consisted of an interaction between opioids and
benzodiazepines (Codeine and Oxazepam, Codeine and Zolpidem, and Morphine and Oxazepam). The coadmin-
istration of opioids and benzodiazepines is associated with an increased risk of overdose deaths and emergency
department visits [85]. Benzodiazepines have also been demonstrated to exert an exacerbating effect on opioid-
mediated respiratory depression [85]. Additionally, a study has noted an elevated fracture risk among older men
who are treated with a combination of opioids and benzodiazepines [86]. The FDA recommends that healthcare
professionals minimize the prescription of opioid medications with benzodiazepines and other CNS depressants,
when possible.
Strengths & limitations of the present study
Study population
This is a preliminary study with a relatively small-sample size (n = 100). Nevertheless, certain measures were taken
to assure that the study population was as representative of the background population as possible. For instance,
5–20 randomized residents were identified by nurses from each of the eight nursing homes, instead of including a
higher number of residents from only a few nursing homes. Furthermore, the participating nursing homes were of
various geographical locations within Aalborg municipality. These approaches provided an advantage in terms of
minimizing possible selection biases and confounders and enhance generalizability. However, in future studies with
larger cohorts, considering both internal and external sources of bias must be taken into consideration. According
to a census conducted by Aalborg municipality in 2019, 1860 nursing home residencies are currently available in
Aalborg municipality. The prevalence of polypharmacy in the elderly has been estimated, by Scandinavian studies,
range from as low as 16.8–30% within the range of 65–74 years to 33–65% at 95+ years [9,27]. Similar results
have been highlighted by systematic review on the prevalence of polypharmacy by the WHO, where the estimated
prevalence was 38.1–91.2% among nursing homes or long-term care facility residents. Our study did not aim
at finding the prevalence but was a purely descriptive study. In future studies, sample size might be estimated if
prevalence is the purpose of the study.
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Lack of comparison
This study did not include a comparison to the rest of the nursing home residents, who received less than five
medications. As far as the aim of this study was to elucidate the patterns and characteristics of polypharmacy,
primarily related to DDIs, the inclusion of these residents with no polypharmacy did not seem relevant. This is
because the amount of potential pairwise interactions increases exponentially with each coprescribed drug [63],
making comparisons irrelevant. However, it is known that polypharmacy is associated with increased age, multi-
morbidity and female sex [3,27,50]. The lack of this comparison in the present study makes it impossible to determine
whether the demographics of the study population differ significantly when compared with a nonpharmaceutical
background population. For example, the female population of this study was 68%. It is difficult to conclude what
this number reflects without a comparable group from the same population (elderly living without polypharmacy
in nursing homes in northern Jutland). While 68% of the population living in nursing homes in Denmark are
females, it cannot be ruled out that a lower proportion of nursing home residents are females in Aalborg, with this
study including these females to a higher degree.
Classification of drugs
By using the ATC codes, promoted by the European Medicines Agency to categorize medications, this study has
tried to utilize a reliable system of drug classification in order to improve reproducibility and transparency. However,
due to the lack of access to information regarding the general health status of the subjects, the categorization of
drugs into therapeutic subgroups was complicated. Because a single drug can have different ATC codes depending
on the therapeutic purpose [46] and lack of knowledge surrounding current health problems might have led to the
condition that some drugs may have been categorized with a bias.
Definition of polypharmacy
Only prescription medications were included in this study, even though herbal and dietary supplements (HDS) can
interact with prescription-based drugs [87,88]. Food supplements are defined as ‘foodstuffs the purpose of which is to
supplement the normal diet and which are concentrated sources of nutrients or other substances with a nutritional
or physiological effect, alone or in combination, marketed in dose form’ (The European Commission [89]). Because
of this broad definition of food supplements alone, and the subsequent difficulty of defining and including all
potentially relevant HDS, it was decided that HDS would be kept out of the scope of this study. However, due to
the importance and practical benefits of such studies, it is recommended for a future investigation. This is mainly
because the use of HDS is on the rise [90]. Cases have even been reported of so-called ‘polyherbacy,’ implying
similarity to those associated with polypharmacy. It has been demonstrated that HDS–drug interactions can lead to
adverse clinical outcomes such as hospitalizations [91]. Since an increase in the number of prescription drugs leads to
an increased risk of DDIs [17], it would be rational to consider that polypharmaceutical patients are also at a higher
risk of HDS–drug interactions. This suggests that there are possibly some potentially clinically relevant HDS–drug
interactions that were not detected in this study. Considering the possible clinical significance of these interactions,
it is relevant to include HDS in future studies to acquire a thorough understanding of potential problems related
to polypharmacy in elderly.
Conclusion
The findings from this study suggest that potentially inappropriate polypharmacy exists among elderly nursing
home residents in Aalborg municipality. A direct correlation was determined between the number of drugs and
number of DDIs. A complex relationship between age and number of drugs became evident, where age was
inversely correlated with number of drugs. A significant difference in number of drugs was observed between the
different age groups, where the highest median number of drugs was determined in the age group of 75–84 years,
whereas the lowest medians of concomitant drugs were seen in the oldest age groups. In line with this finding,
significant differences in the number of potential DDIs were observed in the FDA database between the different
age groups. Tendencies were observed with higher number of drugs and more potential DDIs in females compared
with males. The clinical consequences of the ten most commonly observed potential DDIs in this study consisted
of hyperglycemia, hypotriglyceridemia, hypomagnesemia, fluid and electrolyte disturbances.
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Future perspective
Polypharmacy in the elderly is still under recognized. There is a need for awareness and identification of cases with
inappropriate polypharmacy among elderly. Identification of elderly residents in nursing homes with this condition
can help determine better prevention strategies to enhance the quality of life of these individuals. Our findings
call for further investigation and development of guideline strategies. Establishing a detailed understanding of the
patterns and characteristics of potential inappropriate polypharmacy in the elderly could provide a foundation for
minimizing health and economic consequences caused by inappropriate polypharmacy. To achieve this, a larger
scale study is proposed – collecting sample data from different regions in Denmark and including a control group,
the inclusion of factors such as diet, dietary supplements and consumption of alcohol and tobacco would also yield
further information. Inclusion of medical records would make it possible to determine the incidence rate of the
potential DDIs leading to actual clinical consequences. As it has also been highlighted by multiple Danish studies
on polypharmacy, the current state of polypharmacy in Denmark calls for more thorough medication reviews in
the elderly [92,93], for example, through introduction of the STOPP criteria [38–40] on a broader scale.
Summary points
• Polypharmacy is the concurrent use of more than one drug. Multimorbidity is common among the elderly and a
leading factor of polypharmacy and its risks. Since the elderly population has grown tremendously, the frequency
of polypharmacy can also be expected to increase. Thus, it is important to investigate this phenomenon to
prevent inappropriate polypharmacy.
• Based on the current literature, it is difficult to assess how widespread inappropriate polypharmacy is in Denmark.
Aim
• To identify patterns and characteristics of polypharmacy in the elderly living in nursing homes in Aalborg
municipality, Denmark, by investigating the drug–drug interactions (DDIs) and potential adverse effects.
Methods
• Nursing homes in Aalborg municipality (n = 25) were contacted in November 2019 and asked to supply
information from 20 randomly selected anonymized residents, among those aged 65 years or older, who were
concurrently taking five or more medications. The collected information consisted of age, gender, co-morbidities
and medication list.
• Two different drug interaction databases (one run by the Danish Medication Agency and the other by the US
FDA) were utilized to identify potential DDIs among the medications taken by the residents and to divide DDIs
into three levels of severity based on clinical significance.
• Descriptive statistics were applied.
Results
• The total number of nursing home residents included in this study was 100 (68% females; 32% males; mean
age ± standard deviation [SD]: 82.9 ± 7.7 years).
• Five hundred and eighty-seven (mean ± SD: 5.8 ± 2.2) co-morbidities were registered with the cardiovascular
system as the most commonly affected system. The total number of medications was 848 (mean ± SD: 8.5 ± 2.6)
with the most common being medications related to the gastrointestinal system and metabolism.
• Based on the FDA database, the majority of observed potential interactions were of moderate severity (n = 786,
76.8%), whereas the Danish database identified the majority as being of mild severity (n = 226, 68.6%).
• Statistically significant differences in the number of drugs (p = 0.013) and number of DDIs per resident in the FDA
database (p = 0.039) were observed among the four age groups (65–74, 75–84, 85–94, 95+). No sex-related
difference was found.
• The number of drugs and DDIs were positively correlated.
Discussion & conclusion
• The findings suggest that potentially inappropriate polypharmacy exists among the studied elderly residents.
• Further research is needed to find if this small scope study could similarly reflect characteristics of polypharmacy
in Denmark.
• Strategies and guidelines to prevent inappropriate polypharmacy in nursing homes are warranted.
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